257 related articles for article (PubMed ID: 20209485)
1. Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A.
Ide LM; Iwakoshi NN; Gangadharan B; Jobe S; Moot R; McCarty D; Doering CB; Spencer HT
J Gene Med; 2010 Apr; 12(4):333-44. PubMed ID: 20209485
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
Doering CB; Gangadharan B; Dukart HZ; Spencer HT
Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.
Ide LM; Gangadharan B; Chiang KY; Doering CB; Spencer HT
Blood; 2007 Oct; 110(8):2855-63. PubMed ID: 17569821
[TBL] [Abstract][Full Text] [Related]
4. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
Moayeri M; Hawley TS; Hawley RG
Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
[TBL] [Abstract][Full Text] [Related]
5. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
[TBL] [Abstract][Full Text] [Related]
6. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
7. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells.
Gangadharan B; Parker ET; Ide LM; Spencer HT; Doering CB
Blood; 2006 May; 107(10):3859-64. PubMed ID: 16449528
[TBL] [Abstract][Full Text] [Related]
8. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
10. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
[TBL] [Abstract][Full Text] [Related]
11. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
12. In Utero Transplantation of Placenta-Derived Mesenchymal Stromal Cells for Potential Fetal Treatment of Hemophilia A.
Kumar P; Gao K; Wang C; Pivetti C; Lankford L; Farmer D; Wang A
Cell Transplant; 2018 Jan; 27(1):130-139. PubMed ID: 29562772
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
14. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells.
Moayeri M; Ramezani A; Morgan RA; Hawley TS; Hawley RG
Mol Ther; 2004 Nov; 10(5):892-902. PubMed ID: 15509507
[TBL] [Abstract][Full Text] [Related]
15. Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector.
Ramezani A; Hawley RG
Blood; 2009 Jul; 114(3):526-34. PubMed ID: 19470695
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M
Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221
[TBL] [Abstract][Full Text] [Related]
17. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
18. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
20. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]